Plus Therapeutics (NASDAQ:CNSY) Rating Lowered to “Strong Sell” at Zacks Research

Plus Therapeutics (NASDAQ:CNSY) was downgraded by research analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a research report issued to clients and investors on Wednesday, Zacks reports.

Separately, Weiss Ratings began coverage on shares of Plus Therapeutics in a research report on Tuesday, August 4th. They issued a “sell (e+)” rating on the stock. Two analysts have rated the stock with a Sell rating. According to MarketBeat, the stock presently has a consensus rating of “Sell”.

Plus Therapeutics Stock Up 11.2%

Shares of Plus Therapeutics stock opened at $1.88 on Wednesday. Plus Therapeutics has a 1-year low of $1.49 and a 1-year high of $18.89. The firm has a market capitalization of $14.27 million, a P/E ratio of -0.56 and a beta of 1.47. The firm’s 50-day simple moving average is $2.50.

Plus Therapeutics (NASDAQ:CNSY) last issued its quarterly earnings results on Friday, August 14th. The company reported ($1.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.96) by ($0.35). The company had revenue of $0.41 million during the quarter. Plus Therapeutics had a negative return on equity of 394.17% and a negative net margin of 620.70%. As a group, sell-side analysts expect that Plus Therapeutics will post -4.40 earnings per share for the current year.

About Plus Therapeutics

Plus Therapeutics, Inc is a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for difficult-to-treat cancers. The company’s lead investigational product is RNL, also known as rhenium-186 nanoliposome, an experimental treatment designed to deliver radiation directly to tumors while limiting exposure to surrounding healthy tissue.

Plus Therapeutics is primarily evaluating RNL in cancers of the central nervous system, including recurrent glioblastoma and leptomeningeal metastases.